Psiquiatria

M-A | Eficácia da amisulprida para sintomas depressivos em indivíduos com distúrbios mentais.

12 Nov, 2021 | 13:30h

Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta-analysis – Human Psychopharmacology: Clinical & Experimental

 

Comentário no Twitter

MA: Amisulpride 50 mg/day was associated with a larger reduction of depressive symptoms vs. placebo (SMD= −0.70; −0.92 to −0.49; I2=0.0%), and was found to be comparable to SSRIs (SMD= −0.08; −0.23 to 0.06; I2=0.0%) in dysthymia https://t.co/schW6PbZQK pic.twitter.com/p7St9pE0Cr

— PfOL (@psychopharmacol) November 7, 2021

 

---

M-A | Risco de comportamento suicida nos descendentes em razão de suicídio cometido pelos pais – “A experiência de perder um dos pais por suicídio é um fator de risco forte e independente para comportamento suicida nos descendentes.”

11 Nov, 2021 | 16:04h

Offspring’s risk for suicidal behaviour in relation to parental death by suicide: systematic review and meta-analysis and a model for familial transmission of suicide – The British Journal of Psychiatry

 

Comentário no Twitter

Crucial question to ask all patients:
"Has anyone in your family committed suicide?"

Review of studies shows why: https://t.co/QIysuw9DoX

— Allen Frances (@AllenFrancesMD) November 10, 2021

 

---

Estudo randomizado | Efeitos da cetamina vs. midazolam na neurocognição em 24 horas em pacientes deprimidos com ideação suicida.

11 Nov, 2021 | 16:02h

Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation – The Journal of Clinical Psychiatry (link para o resumo – $ para o texto completo)

Comentários: Ketamine Rapidly Improves Cognitive Function Making Those in Suicidal Crisis Less Likely to Harm Themselves – Columbia University Irving Medical Center

---

Estudo randomizado | Rastreamento universal no ensino médio pode ajudar a identificar e iniciar o tratamento de depressão em adolescentes.

11 Nov, 2021 | 16:00h

Screening in High Schools to Identify, Evaluate, and Lower Depression Among Adolescents: A Randomized Clinical Trial – JAMA Network Open

Comunicado de imprensa: School-based screening increases identification of, treatment for depression – Penn State

Comentários:

Universal Depression Screening in Schools—Promises and Challenges in Addressing Adolescent Mental Health Need – JAMA Network Open

Universal School-Based Depression Screening May Connect More Students to Care – Psychiatric News Alert

 

Comentários no Twitter

In a randomized clinical trial including 12,909 students at 14 Pennsylvania public high schools, adolescents randomized to receive a depression screen and identified with symptoms had 2.1 times higher odds of initiating depression treatment. https://t.co/b0l5ShCiHf pic.twitter.com/XptJDrH0Ne

— JAMA Network Open (@JAMANetworkOpen) November 8, 2021

 

---

Novo teste para demência traz mais questões do que respostas – “Uma avaliação de 5 minutos em um iPad poderia transformar o rastreamento da demência – ou sobrecarregar o sistema de saúde com usuários preocupados.”

11 Nov, 2021 | 15:57h

A New Dementia Test Raises More Questions Than Answers – Wired

---

Amplo estudo observacional sugere a associação entre antipsicóticos que aumentam a prolactina e risco aumentado de câncer de mama (OR = 1,56 para mais de 5 anos de exposição); por outro lado, antipsicóticos poupadores de prolactina (clozapina, quetiapina ou aripiprazol) não estão associados a tal risco.

10 Nov, 2021 | 12:36h

Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland – The Lancet Psychiatry (link para o resumo – $ para o texto completo)

Comentário: Choosing between antipsychotics to reduce the risk of breast cancer in women with schizophrenia – The Mental Elf

 

Comentário no Twitter

Nested case-control study: ≥5 years exposure to prolactin-sparing APDs was not associated with an increased risk of breast cancer vs.<1 year exposure (aOR=1.19; 0.90–1.58). The opposite was observed with APDs that increase prolactin (aOR=1.56; 1.27–1.92) https://t.co/LwCVyTH051

— PfOL (@psychopharmacol) September 12, 2021

 

---

Entre os adolescentes, o tempo de diversão em telas dobrou durante a pandemia, afetando sua saúde mental.

3 Nov, 2021 | 11:14h

Comunicado de imprensa: Adolescents’ recreational screen time doubled during pandemic, affecting mental health – University of California, San Francisco

Estudo original: Screen Time Use Among US Adolescents During the COVID-19 Pandemic: Findings From the Adolescent Brain Cognitive Development (ABCD) Study – JAMA Pediatrics

Comentário: Kids nearly doubled screen time during the pandemic, but there is something you can do about it – CNN

 

Comentário do autor no Twitter

🚨 New @UCSF study in @JAMAPediatrics 🚨

Recreational #ScreenTime in teens doubled to nearly 8⃣ hours per day during the #COVID19 #pandemic, excluding screen time for school.

⬆️ screen time linked to
⬇️ mental health
⬆️ stress
⬇️ social support

🔗 https://t.co/04RhNIAh4r 📺 pic.twitter.com/f2PvETdFbF

— Jason Nagata, MD (@jasonmnagata) November 1, 2021

 

---

Diretriz NICE | Encefalomielite (ou encefalopatia) miálgica/síndrome da fadiga crônica: diagnóstico e tratamento.

1 Nov, 2021 | 10:56h

Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management – National Institute for Health and Care Excellence

Comentários:

Chronic fatigue syndrome advice scraps exercise therapy – BBC

ME exercise therapy guidance scrapped by health watchdog Nice – The Guardian

---

Prescrição de estimulantes está associada a aumento dos riscos de curto prazo de eventos cardiovasculares em idosos.

29 Out, 2021 | 14:34h

Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults – JAMA Network Open

Comentários:

Use of stimulants in older adults associated with higher risk for cardiovascular events in first month – University of Toronto

Stimulants Linked to Early Risk of CV Events in Elderly – TCTMD

Stimulants May Pose Short-Term Cardiovascular Risks in Older Adults – Psychiatric News Alert

---

Estudo randomizado | Tratamento precoce com fluvoxamina reduziu o risco de cuidado de emergência e internação entre pacientes com COVID-19.

28 Out, 2021 | 16:22h

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial – The Lancet Global Health

Comentários:

Expert reaction to study looking at fluvoxamine as a COVID-19 treatment in high-risk outpatients with early-diagnosed COVID-19 – Science Media Centre

The TOGETHER Trial: COVID-19 and Fluvoxamine Take Two – REBEL EM

The antidepressant fluvoxamine can keep COVID-19 patients out of the hospital – ScienceNews

Conteúdos relacionados:

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 

Comentário no Twitter

NEW in @LancetGH: Using SSRI #fluvoxamine to treat high-risk outpatients with early-diagnosed #COVID19 reduced the need for prolonged observation in an emergency setting or hospitalisation: largest trial to date. https://t.co/BVtMju74lp @TogetherTrial pic.twitter.com/F1FnZuyqdY

— The Lancet (@TheLancet) October 27, 2021

 

---